Table 1.
Clinicopathologic and genomic characteristics of 328 patients who received durvalumab after chemoradiotherapy
| Clinical Characteristic | N = 328 |
|---|---|
| Age, median (range) | 69 (44–86) |
| Sex | |
| Male | 170 (51.8) |
| Female | 158 (48.2) |
| Smoking status | |
| Current/Former | 313 (95.4) |
| Never | 15 (4.6) |
| Histology | |
| Nonsquamous | 228 (69.5) |
| Squamous | 100 (30.5) |
| Oncogene diver (NSQ)a | |
| KRASb | 75 (42.9) |
| EGFR | 3 (1.7) |
| Others | 18 (10.3) |
| None identified | 79 (45.1) |
| Not assessed | 53 |
| PD-L1 TPS | |
| ≥90% | 40 (14.6) |
| 50–89% | 61 (22.3) |
| 1–49% | 75 (27.4) |
| <1% | 98 (35.7) |
| Not assessed | 54 |
| Stage (AJCC 8TH Edition) | |
| IIIA | 121 (37.0) |
| IIIB | 158 (48.0) |
| IIIC | 49 (15.0) |
| Radiation dose | |
| 54–58.4 Gy | 12 (3.7) |
| 60 Gy | 265 (80.8) |
| 62–70 Gy | 51 (15.5) |
| Chemotherapy regimen | |
| Carboplatin + Paclitaxel | 151 (45.9) |
| Carboplatin + Pemetrexed | 75 (22.9) |
| Cisplatin + Pemetrexed | 72 (22.0) |
| Cisplatin + Etoposide | 30 (9.2) |
| Institution | |
| MSKCC | 180 (54.9) |
| DFCI | 148 (45.1) |
NSQ nonsquamous
a175 cases with comprehensive genomic profiling
bKRAS allele subtypes: G12C (N = 33), G12V (N = 18), G12D (N = 10), G13x (N = 4), and other KRAS (N = 10). Other driver mutations: ALK, BRAF, MET, and HER2